Diamyd Medical AB Income Statement

Financials in millions SEK. Fiscal year is September - August.

Millions SEK. Fiscal year is Sep - Aug.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb '26 Feb 28, 2026	Aug '25 Aug 31, 2025	Aug '24 Aug 31, 2024	Aug '23 Aug 31, 2023	Aug '22 Aug 31, 2022	Aug '21 Aug 31, 2021
Revenue	0.36	0.13	0.13	0.55	0.45	0.25
Revenue Growth (YoY)	98.90%	-	-76.19%	20.26%	79.45%	-25.81%
Cost of Revenue	3.4	3.84	3.71	3.63	4.4	2.5
Gross Profit	-3.03	-3.71	-3.58	-3.09	-3.95	-2.25
Selling, General & Admin	64.13	56.55	44.79	39.7	31.93	25.63
Research & Development	137.72	119.5	96.48	69.91	75.57	56.86
Other Operating Expenses	-3.37	-3.03	-3.16	-1.72	-0.89	0.55
Operating Expenses	205.46	179.53	143.69	112.76	110.99	83.82
Operating Income	-208.49	-183.23	-147.27	-115.85	-114.94	-86.07
Interest Expense	-	-	-0.01	-0	-0.25	-0.45
Interest & Investment Income	4.9	2.34	3.75	1.05	0.07	0
Earnings From Equity Investments	-	-	6.12	-4.96	-3.24	-
Currency Exchange Gain (Loss)	4.16	4.16	0.12	3.68	8.19	2.15
Other Non Operating Income (Expenses)	-0	-0	-0	0	-0	0
EBT Excluding Unusual Items	-199.43	-176.73	-137.3	-116.07	-110.17	-84.37
Gain (Loss) on Sale of Investments	-1.03	6.96	-9.14	-	6.65	144.41
Asset Writedown	-	-	-5.41	-	-	-
Pretax Income	-200.47	-169.78	-151.85	-116.07	-103.52	60.05
Net Income	-200.47	-169.78	-151.85	-116.07	-103.52	60.05
Net Income to Common	-200.47	-169.78	-151.85	-116.07	-103.52	60.05
Net Income Growth	-	-	-	-	-	518.46%
Shares Outstanding (Basic)	130	113	95	78	77	70
Shares Outstanding (Diluted)	130	113	95	78	77	70
Shares Change (YoY)	28.78%	18.81%	20.98%	2.29%	9.65%	0.90%
EPS (Basic)	-1.55	-1.51	-1.60	-1.48	-1.35	0.86
EPS (Diluted)	-1.55	-1.51	-1.60	-1.48	-1.35	0.86
EPS Growth	-	-	-	-	-	512.92%
Free Cash Flow	-170.4	-179.73	-137.21	-122.4	-127.87	-113.69
Free Cash Flow Per Share	-1.31	-1.60	-1.45	-1.56	-1.67	-1.63
Operating Margin	-57593.92%	-140949.23%	-113287.69%	-21217.22%	-25316.30%	-34020.55%
Profit Margin	-55377.62%	-130597.69%	-116807.69%	-21258.79%	-22801.10%	23733.60%
Free Cash Flow Margin	-47072.65%	-138254.61%	-105543.08%	-22418.32%	-28165.42%	-44937.94%
EBITDA	-201.62	-176.73	-141.69	-110.98	-110.55	-85.29
D&A For EBITDA	6.87	6.5	5.58	4.87	4.38	0.78
EBIT	-208.49	-183.23	-147.27	-115.85	-114.94	-86.07
Revenue as Reported	4.5	5.02	4.36	3.75	2.58	0.44

Updated Feb 28, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.